Compounds > 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2-2-dimethylprpyl)-3-pyridinecarboxamide

6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2-2-dimethylprpyl)-3-pyridinecarboxamide and Psoriasis

6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2-2-dimethylprpyl)-3-pyridinecarboxamide has been researched along with Psoriasis* in 1 studies

Other Studies

1 other study(ies) available for 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2-2-dimethylprpyl)-3-pyridinecarboxamide and Psoriasis

Article	Year
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. Journal of medicinal chemistry, 2010, Mar-25, Volume: 53, Issue:6 Topics: Arthritis, Rheumatoid; Chronic Disease; Clinical Trials, Phase II as Topic; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Indoles; Inflammatory Bowel Diseases; Models, Molecular; Molecular Structure; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Binding; Psoriasis; Pyridones; Pyrimidines; Treatment Outcome	2010

Article

Year

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

Journal of medicinal chemistry, 2010, Mar-25, Volume: 53, Issue:6

Topics: Arthritis, Rheumatoid; Chronic Disease; Clinical Trials, Phase II as Topic; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Indoles; Inflammatory Bowel Diseases; Models, Molecular; Molecular Structure; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Binding; Psoriasis; Pyridones; Pyrimidines; Treatment Outcome

2010